Entera Bio (ENTX)
Develops oral peptide therapies through its N-Tab delivery platform.
Something off on this page? Send us feedback.
Develops oral peptide and protein-replacement therapies using N-Tab, with EB613 its most advanced osteoporosis candidate. Its clinical pipeline also includes EB612 for hypoparathyroidism and EB618 for metabolic syndromes, alongside OPKO collaborations on oral peptide programs.
Develops oral peptide and protein-replacement therapies through N-Tab®, a proprietary delivery platform. EB613, its most advanced candidate, is an oral PTH program for osteoporosis; EB612 targets hypoparathyroidism and EB618 targets metabolic syndromes.
In Jerusalem, the clinical-stage business develops its pipeline and pursues selected development and commercial partnerships. OPKO is its documented external-development partner, with collaborations spanning oral OXM and long-acting PTH programs.
Program progress depends on clinical development and regulatory pathways. The long-acting PTH collaboration gives Entera and OPKO shared ownership and development-cost responsibilities, while the oral OXM program has a different ownership and cost-sharing structure.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 22, 2026 | Cantor Fitzgerald | Initiate | Rating: — | |
| Sep 18, 2026 | UBS | Target | Target: — | Target: $9 |
| Sep 18, 2026 | Leerink Partners | Target | Target: — | Target: $9 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $11.3M · Total debt $425.0K · Total assets $19.5M · Shareholders' equity $7.3M
- Revenue
- $0
- Operating income
- −$4.6M
- Net income
- −$7.3M
No dividends on record.
| Institutions | 6.20% | 10.73M shares | |
|---|---|---|---|
| 28 holders · as of Jun 30, 2026 | |||
| Insiders | 1.32% | 2.28M shares | |
| 10 holders · as of Aug 7, 2026 | |||
| Strategic holders | 7.08% | 12.25M shares | |
| 1 holder · as of Aug 4, 2026 | |||
| Other | 85.40% | 147.88M shares | |
| remainder | |||
173.14M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (173.14M in the company's Sep 22, 2026 report, 49.29M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
TCG Crossover GP III, LLCStrategic | 7.08% | 12.25M | filed Aug 4, 2026 |
Biotechnology Value Fund L PInstitution | 5.30% | 9.17M | filed Aug 4, 2026 |
Knoll Capital Management, LLCInstitution | 3.40% | 5.88M | as of Jun 30, 2026 |
BVF Inc/ILInstitution | 1.40% | 2.43M | as of Jun 30, 2026 |
Miranda Jayne ToledanoInsiderdirector, officer: Chief Executive Officer | 0.49% | 847,135 | filed Jul 16, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Mar 9, 2026 | Geno J. Germano | director | +20,000 | $1.30 |
| Mar 5, 2026 | Sean Ellis | director | +10,000 | $1.23 |
| Feb 9, 2026 | Sean Ellis | director | +18,000 | $1.24 |
| Feb 10, 2026 | Geno J. Germano | director | +20,000 | $1.49 |
| Feb 10, 2026 | Haya Taitel | director | +7,500 | $1.48 |
- Amgen
Established osteoporosis medicines with bone-building and antiresorptive options
- Ascendis Pharma (ADR)
YORVIPATH PTH replacement for chronic hypoparathyroidism
- AstraZeneca (ADR)
Phase III PTH1R agonist program for chronic hypoparathyroidism
- Septerna
Next-generation oral PTH1R agonists for hypoparathyroidism
- Novo Nordisk (ADR)
Oral GLP-1 obesity medicines and a broad semaglutide franchise
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Entera Bio | $2.98 | −0.17% | $145.9M | — | — | — | — |
| Amgen | $409.75 | −0.11% | $212.19B | 24.4 | 17.5 | 5.6 | +9.7% |
| Ascendis Pharma (ADR) | $237.57 | +0.09% | $14.76B | 18.1 | 33.8 | 12.2 | +108.2% |
| AstraZeneca (ADR) | $168.45 | +0.05% | $260.70B | 25.2 | 15.8 | 4.2 | +6.4% |
| Septerna | $40.38 | 0.00% | $1.74B | — | — | 17.6 | +22,375.6% |
| Novo Nordisk (ADR) | $39.42 | +0.03% | $176.83B | 9.9 | 16.2 | 3.5 | +1.3% |
| Median | 21.3 | 16.8 | 5.6 | +9.7% |